Small rodents fauna in young Japanese cedar and cypress stands, Nara prefecture.

Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure

Objective: To determine the efficacy of the antihistamine bepotastine on treating nasal symptoms in patients with Japanese cedar and cypress pollinosis, based on two previous studies that looked at bepotastine OD's inhibitory effect on symptom onset after exposure. Design and methods: Randomized double-blind placebo controlled, parallel study. Twenty-eight volunteers with Japanese cedar and cyp...

Allergic Sensitization to Perennial Allergens in Adults and Children Sensitized to Japanese Cedar or Japanese Cypress Pollen in Japan

In Japan, seasonal allergic rhinitis in the spring due to exposure to Japanese cedar or Japanese cypress pollen is common. However, the allergic profile for perennial allergens in spring pollinosis remains unclear. Therefore, in this study, we investigated the allergic profiles of 652 patients with rhinitis. Total serum IgE, serum-specific IgE, and blood eosinophil counts were measured. Allergi...

Serotyping of human group A rotaviruses in Nara Prefecture, Japan.

Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen.

BACKGROUND Pollens from species of the Cupressaceae family are one of the most important causes of respiratory allergies worldwide. Many patients with pollinosis have specific IgE to both allergens from Japanese cedar and Japanese cypress pollen. We set out to identify T cell epitopes in Cha o 2, the second major allergen of Japanese cypress pollen. METHODS T cell lines (TCL) and T cell clone...

Early interventional treatment with intranasal corticosteroids is superior to post-onset treatment in Japanese cedar/cypress pollinosis

Method We designed a three-armed, double-blinded, randomized, placebo-controlled trial. Patients received mometasone furoate nasal spray (EIT group: n=25), placebo (n=25), or 4 weeks of placebo followed by 8 weeks of mometasone (POT group: n=25) for a 12-week period starting on February 1, 2011. The primary endpoint was the comparison of the total nasal symptom score (TNSS) among the three grou...